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Abstract 
Facile derivatization of paclitaxel (Ptx) and subsequent “drug-initiated” synthesis of well-
defined Ptx-polymer prodrugs was performed from nitroxide-mediated polymerization or 
reversible addition-fragmentation chain transfer polymerization. Short polyisoprene (Mn = 
2640–4310 g.mol-1, Ð ~1.1) or poly[oligo(ethylene glycol) methyl ether methacrylate)] (Mn = 
5580–7530 g.mol-1, Ð ~1.2) chains were grown from Ptx in a controlled fashion and enabled, 
for the first time, the formation of either self-stabilized, all-hydrophobic Ptx-polymer prodrug 
nanoparticles or their PEGylated counterparts. They exhibited average diameters in the 110–
235 nm range, great colloidal stability in PBS and cell culture medium, high drug loadings (up 
to 32 wt.%) and cytotoxicity similar to that of the parent drug on three different cancer cell 
lines (A549, L1210 and MCF-7). This versatile approach is expected to provide more potent 
anticancer nanocarriers and rejuvenate the development of Ptx-based nanomedicines. 
 
 
Keywords 
Polymer, prodrug, paclitaxel, nanoparticles, PEGylation, cancer 
  
3 
 
Introduction 
Paclitaxel (Ptx), a naturally occurring diterpene alkaloid,
1
 is one of the most potent 
chemotherapeutic agents used in the clinics for the treatment of a broad range of human solid 
tumors including breast, lung, ovarian, non-small cell, head and neck cancers.
2-4
 Despite the 
important therapeutic potential of Ptx, its use is limited by its poor water solubility (< 3 
μg.mL-1)5 and absence of ionizable groups to enable Ptx salt formation. Thus, Ptx is 
administered as an emulsion from a mixture with Cremophor EL (polyoxyl 35 castor oil) and 
dehydrated ethanol (50/50, v/v), under the name of Taxol.
6
 However, Ptx formulations are 
incompatible with certain infusion sets and exhibit short-term colloidal stability, leading to 
precipitation. In addition, Cremophor EL is often associated with the occurrence of several 
side effects including hypersensitivity reactions, hematological toxicity, peripheral 
neurotoxicity and neuropathy.
7-10
 
To overcome these limitations, nanoscale Ptx-loaded systems have been developed 
such as emulsions, liposomes, micelles, nanoparticles and dendrimers, but only a few of them 
have shown advanced clinical translation.
11
 For instance, Abraxane (albumin-bound Ptx 
nanoparticles),
12
 which was FDA-approved for the treatment of metastatic breast cancer, and 
Genexol-PM (Ptx-loaded polymer micelles),
13
 which is currently under phase II clinical trials, 
have both demonstrated reduced side effects. However, they did not exhibit any improvement 
in terms of pharmacokinetics (i.e., low plasma half-lives) because of rapid release of Ptx from 
the carrier, thus failing to deliver Ptx in a sustained manner. Conversely, Ptx-loaded 
PEGylated polypeptide micelles (NK105) showed reduced systemic neurotoxicity, greater 
plasma concentration and enhanced therapeutic efficacy compared to free Ptx during Phase 
I/II clinical trials.
14
 Nevertheless, the primary endpoint of a phase III related to progression-
free survival did not meet the expected statistical criteria.  
To solve these issues, polymer prodrugs consisting in the covalent linkage of Ptx to 
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polymers, have been developed.
15
 Polymer prodrugs indeed exhibit numerous advantages 
over traditional drug-loaded nanocarrier including absence of “burst release” (that is, the 
quick release post-administration of a significant fraction of the drug only adsorbed at the 
surface of the nanoparticles), enhanced drug loadings and drug solubility improvement.
16
 The 
most extensively used strategy to produce Ptx-polymer prodrugs consists in the linkage of Ptx 
by post-functionalization to preformed polymers (“grafting to” method), such as polyethylene 
glycol (PEG),
17
 poly(L-glutamic acid) (PGA),
18
 polylactide (PLA),
19,20
 dendrimer,
21,22
 and 
other block polymers.
23-25
 However, moderate conjugation efficacies, tedious multistep 
synthetic pathways and difficulty to accurately position the drug on the polymer chain were 
often witnessed. The polymerization of Ptx-conjugated monomers (“grafting through” 
method) was also investigated, but to a lesser extent.
26,27
  
By analogy with polymer synthesis, the “grafting from” approach (also called “drug-
initiated”), which consists in the controlled growth of polymer chain from a drug, met with 
remarkable success for the design of various prodrug nanocarriers.
28
 Conversely to the 
previously-described approaches, drug-initiated polymer prodrugs exhibit several cutting-
edge advantages: (i) they are easy to synthesize (only a few synthetic steps are required); (ii) 
they have a simple, well-defined structure with one drug attached at the extremity of each 
polymer chain; (iii) high drug loading can be achieved by targeting short polymer chain; (iv) 
this strategy can be applied to different drugs, thus conferring an important versatility in terms 
of the targeted pathology and (v) different polymers can be grown from the drug, which allow 
tuning of the solubility of the resulting materials; from water-soluble prodrugs to self-
assembled nanostructures. The robustness of the drug-initiated method has been illustrated by 
its application to a variety of different polymer prodrugs constructed by either ring-opening 
polymerization (ROP)
29-32
 or reversible-deactivation radical polymerization (RDRP), 
including nitroxide-mediated radical polymerization (NMP) or reversible addition-
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fragmentation chain transfer (RAFT) polymerization.
33-40
 Promising in vitro and in vivo 
results in the field of cancer therapy have been reported over the past few years. However, 
two major concerns currently restricting the wide applicability of this approach still remain: 
(i) all hydrophobic drug-polymer nanocarriers (i.e., where both the drug, such as Ptx, and the 
polymer are hydrophobic) exhibit poor colloidal stability, thus requiring post-stabilization by 
means of macromolecular surfactants and (ii) direct synthesis of PEGylated prodrugs which 
would open the door to long-circulating (stealth) Ptx-based conjugates, has never been 
reported. Whereas PEGylated prodrugs is of immediate interest to obtain high and rather 
constant systemic concentrations after administration to target tumors by the EPR effect,
41
 
stable nanocarriers made of all-hydrophobic polymer prodrugs could advantageously be used 
to allow more flexibility in terms of the nature of the polymer and the drug used. Also, having 
different nanocarriers’ surface properties could be crucial regarding their interaction with the 
biological medium and their fate in vivo.
42
 
Herein, we tackle these issues and report on a global approach based on the facile 
derivatization of Ptx followed by subsequent “drug-initiated” RDRP to design surfactant-free, 
Ptx-polymer prodrug nanocarriers with opposite surface properties – either hydrophobic or 
PEGylated (Scheme 1), high drug loadings, great colloidal stability in biological media and 
anticancer activity similar to that of the parent drug on three different cancer cell lines. This 
versatile approach is expected to provide more potent nanocarriers for cancer therapy and 
rejuvenate the development of Ptx-based nanomedicines. 
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Scheme 1. Design of self-stabilized (a) hydrophobic and (b) PEGylated paclitaxel (Ptx) 
polymer prodrug nanoparticles by the drug-initiated method. 
 
Experimental Section 
Materials 
Paclitaxel (Ptx) was purchased from Sequoia Research Products Limited (UK). N-tert-Butyl-
N-[1-diethylphosphono-(2,2-dimethylpropyl)] nitroxide (SG1, 85%) was obtained from 
Arkema (France). Diglycolic anhydride and tetrabutylammonium fluoride were purchased 
from Thermo Fisher Scientific (US). 4-Cyano-4-
[(dodecylsulfanylthiocarbonyl)sulfanyl]pentanol (CDP) and oligo(ethylene glycol) methyl 
ether methacrylate (Mn = 300 g.mol
-1
, OEGMA) were purchased from Sigma-Aldrich. 2-[N-
tert-Butyl-N-(1-diethoxyphosphoryl-2,2-di-methylpropyl)aminoxy] propionic acid (AMA-
SG1),
43 digly-AMA-SG1 and digly-PI were prepared according to published methods.36 
LysoTracker Red was purchased from Life Technologies. DMEM and fetal bovine serum 
(FBS) were purchased from Dulbecco (Invitrogen, France). Penicillin was purchased from 
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Lonza (Verviers, Belgium). All other materials were purchased from Aldrich at the highest 
available purity and used as received. 
 
Analytical methods 
Nuclear Magnetic Resonance Spectroscopy (NMR). NMR spectroscopy was performed in 
5 mm diameter tubes in CDCl3 or DMSO-d6 at 25 °C. 
1
H and 
13
C NMR spectroscopy was 
performed on a Bruker Avance 300 spectrometer at 300 MHz (
1
H) or 75 MHz (
13
C). The 
chemical shift scale was calibrated on the basis of the internal solvent signals. 
Mass spectra. Mass spectra were recorded with a Bruker Esquire-LC instrument. High-
resolution (HR) mass spectra (electron spin ionization, ESI) were recorded on an ESI/TOF 
(LCT, Waters) LC-spectrometer.  
Size Exclusion Chromatography (SEC). SEC was performed at 30 °C with two columns 
from Polymer Laboratories (PL-gel MIXED-D; 300 × 7.5 mm; bead diameter 5 mm; linear 
part 400 to 4 × 10
5
 g.mol
-1
) and a differential refractive index detector (SpectraSystem RI-150 
from Thermo Electron Corp.). The eluent was chloroform at a flow rate of 1 mL.min
-1
 and 
toluene was used as a flow-rate marker. This technique allowed Mn (the number-average 
molar mass), Mw (the weight-average molar mass), and Mw/Mn (the dispersity, Ð) to be 
determined. The calibration curve for Ptx-digly-PI was based on polystyrene (PS) standards 
(peak molar masses, Mp = 162–523 000 g.mol
−1) from Polymer Laboratories. A polyisoprene 
(PI) calibration curve was then constructed by converting the PS standard peak molecular 
weights, MPS, to PI molecular weights, MPI, using Mark- Houwink-Sakurada (MHS) constants 
determined for both polymers in CCl4 at 25 °C. For PI, the MHS constants used were KPI = 
2.44 × 10
4
 and αPI = 0.712. For PS, KPS = 7.1 × 10
4
 and αPS = 0.54 (MW < 16700 g.mol
-1
) or 
KPS = 1.44 × 10
4
 and αPS = 0.713 (MW > 16700 g.mol
-1
).
44 The calibration curve for Ptx-digly-
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POEGMA was based on poly(methyl methacrylate) (PMMA) standards (peak molar masses, 
Mp = 625−625 500 g.mol
−1
) from Polymer Laboratories. 
Dynamic Light Scattering (DLS) and Zeta Potential. Nanoparticle diameters (Dz) and zeta 
potentials (ζ) were measured by dynamic light scattering (DLS) with a Nano ZS from 
Malvern (173° scattering angle) at a temperature of 25 °C. The surface charge of the 
nanoparticles was investigated by ζ-potential (mV) measurement at 25 °C after dilution with 1 
mM NaCl, using the Smoluchowski equation. 
Cryogenic Transmission electron microscopy (Cryo-TEM). The morphology of the 
different nanoparticles was examined by Cryo-TEM. Briefly, 5 μL of the nanoparticle 
suspension (5 mg.mL
-1
) was deposited on a Lacey Formvar/carbon 300 mesh copper 
microscopy grid (Ted Pella). Most of the drop was removed with a blotting filter paper and 
the residual thin film remaining within the holes was vitrified by plunging into liquid ethane. 
Samples were then observed using a JEOL 2100HC microscope. 
Fluorescence spectroscopy. Emission spectra were obtained using a LS 50B fluorescence 
spectrometer from Perkin Elmer. All measurements were conducted at room temperature (~25 
ºC) with a spectral bandwidth (ex, em) of 2.5 nm and λex = 422 nm. 
 
Synthesis methods 
Synthesis of Ptx-digly-AMA. Digly-AMA-SG1 (0.20 g, 0.39 mmol), DMAP (0.07 g, 0.6 
mmol), and EDC.HCl (0.11 g, 0.6 mmol) were dissolved in 5 mL anhydrous CH2Cl2 and 
mixed in a reaction flask under argon at room temperature. After 15 min, a solution of 
paclitaxel (0.25 g, 0.3 mmol) in DMF (1 mL) was added into the flask dropwise. After stirring 
at 30 °C for 22 h, the mixture was poured into 30 mL of EtOAc. The organic phase was 
washed with brine before being dried over MgSO4. The residue was concentrated under 
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reduced pressure and purified by flash chromatography (SiO2, from DCM/EtOAc = 2/1 to 
DCM/EtOAc = 1/1, v/v) to give 0.32 g Ptx-digly-AMA as a white solid. Yield = 82%. 
1
H 
NMR (300 MHz, CDCl3) of the major diastereomer was shown for clarity: δ = 8.16 (d, 2H, J 
= 7.5 Hz), 7.76 (d, 2H, J = 7.5 Hz), 7.34-7.63 (m, 11H), 7.09 (d, 1H, J = 9.0 Hz), 6.21-6.30 
(m, 2H), 6.05 (d, 1H, J = 9.0 Hz), 5.70 (d, 1H, J = 6.9 Hz), 5.59 (t, 1H, J = 2.7 Hz), 4.99 (dd, 
1H, J = 8.1 Hz, J = 1.5 Hz), 4.66 (dd, 1H, J = 6.6 Hz, J = 6.6 Hz), 3.88-4.44 (m, 14H), 3.83 (d, 
1H, J = 6.8 Hz), 3.38 (d, 1H, J = 26.4 Hz), 2.36-2.61 (m, 6H), 2.23 (s, 3H), 2.14-2.19 (m, 1H), 
1.94 (s, 3H), 1.84-1.89 (m, 1H), 1.80 (d, 1H, J = 3.6 Hz), 1.68 (s, 3H), 1.46 (d, 3H, J = 6.9 
Hz), 1.22-1.30 (m, 9H), 1.06-1.15 (m, 24H). 
13
C NMR (75 MHz, CDCl3) of the mixture of the 
diastereomers: δ = 203.8, 173.6, 171.2, 169.9, 169.3, 168.9, 167.7, 167.1 (d), 167.0, 142.4, 
136.8 (d), 133.5, 133.1, 132.1 (d), 130.3 (2C), 129.4, 129.2 (2C), 128.8 (2C), 128.7 (2C), 
128.5, 127.3, 127.1, 126.6 (2C), 84.5, 82.2, 81.2, 79.1, 76.5, 75.5, 75.2, 74.5, 72.2 (d),70.54, 
68.6, 68.0, 62.6 (d), 61.9 (d), 61.75, 59.0 (d), 58.6, 52.7, 45.6, 43.3 (d), 35.6, 29.6 (t), 27.9, 
26.9, 22.8, 22.3, 22.1, 20.9, 19.3 (d), 16.5 (d), 16.3, 16.2, 14.8, 9.7. MS (ESI+): m/z = 1385.4 
(M + Na)
+
. 
Polymerization of isoprene from Ptx-digly-AMA. Ptx-digly-AMA (55 mg, 0.04 mmol) was 
placed in a 15 mL capacity pressure tube (Ace Glass 8648-164) fitted with plunger valves and 
thermowells. Isoprene (0.8 mL, 8.0 mmol) and dioxane (0.8 mL) were added and the tube was 
subjected to three cycles of freeze-thaw degassing, then backfilled with argon. The tube was 
placed in an oil bath at 115 °C for 4 (P1), 8 (P2), or 16 h (P3) and then cooled to room 
temperature by placing in a bath of cold water. The residue was concentrated under reduced 
pressure and precipitated in methanol to give Ptx-digly-PI as a colorless product. Another two 
polymerizations were performed for 16 h with [isoprene]0/[Ptx-digly-AMA]0 = 300/1 (P4) 
and 400/1 (P5).  
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Synthesis of Digly-CDP. 4-Cyano-4-[(dodecylsulfanylthiocarbonyl)sulfanyl]pentanol (CDP) 
(0.20 g, 0.5 mmol) was mixed with diglycolic anhydride (0.15 g, 1.25 mmol) and 
triethylamine (0.35 mL, 2.5 mmol) in anhydrous CH2Cl2 (4 mL) and the reaction mixture was 
stirred at room temperature for 26 h under argon. The mixture was poured into 20 mL of 
CH2Cl2 and the organic phase was washed with 1 M HCl and brine before being dried over 
MgSO4. The residue was concentrated under reduced pressure to give 0.23 g of Digly-CDP as 
an orange liquid. Yield = 88%. 
1
H NMR (300 MHz, CDCl3): δ= 4.24-4.27 (m, 6H), 3.33 (t, 
2H, J = 7.5 Hz), 1.95-2.33 (m, 4H), 1.87 (s, 3H), 1.70 (m, 2H), 1.26-1.40 (m, 18H), 0.88 (t, 
3H, J = 6.6 Hz). 
13
C NMR (75 MHz, CDCl3): δ =217.2, 171.4, 170.4, 119.2, 69.0, 68.8, 64.3, 
45.6, 37.1, 35.5, 31.9, 29.6 (2C), 29.5, 29.4, 29.3, 29.0, 28.9, 27.7, 24.9, 24.2, 22.7, 14.1. MS 
(ESI+): m/z = 528.2 (M + Na)
+
. 
Synthesis of Ptx-digly-CDP. Digly-CDP (0.45 g, 0.9 mmol), DMAP (0.12 g, 1.0 mmol), and 
EDC.HCl (0.2 g, 1.0 mmol) were dissolved in 5 mL anhydrous CH2Cl2 and mixed in a 
reaction flask under argon at room temperature. After 15 min, a solution of paclitaxel (0.30 g, 
0.35 mmol) in DMF (1 mL) was added into the flask dropwise. After being stirred at 30 °C 
for 26 h, the mixture was poured into 50 mL of EtOAc. The organic phase was washed with 
NaHCO3 aqueous solution and brine before being dried over MgSO4. The residue was 
concentrated under reduced pressure and purified by flash chromatography (SiO2, from 
DCM/EtOAc = 5/1 to DCM/EtOAc = 1/1, v/v) to give 0.20 g Ptx-digly-CDP as a yellow 
sticky solid. Yield = 43%. 
1
H NMR (300 MHz, CDCl3):δ = 8.17 (d, 2H, J = 7.2 Hz), 7.77 (d, 
2H, J = 7.5 Hz), 7.35-7.61 (m, 11H), 7.09 (d, 1H, J = 8.7 Hz), 6.18-6.29 (m, 2H), 6.05 (d, 1H, 
J = 9.0 Hz), 5.70 (d, 1H, J = 6.9 Hz), 5.59 (m, 1H), 4.99 (dd, 1H, J = 7.8 Hz, J = 1.8 Hz), 
4.11-4.48 (m, 9H), 3.83 (d, 1H, J = 6.3 Hz), 3.31 (t, 2H, J = 6.6 Hz), 2.48 (s, 3H), 2.35-2.61 
(m, 3H), 2.23 (s, 3H), 2.14-2.25 (m, 3H), 1.94 (s, 3H), 1.85 (s. 3H), 1.80-2.01 (m, 2H), 1.68 
(s, 3H), 1.65 (m, 2H), 1.14-1.39 (m, 27H), 0.88 (t, 3H, J = 6.3 Hz). 
13
C NMR (75 MHz, 
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CDCl3): δ = 203.8, 171.2, 169.8, 169.0, 167.7, 167.1, 167.0, 162.5, 142.5, 136.8, 133.6 (2C), 
132.9,131.9, 130.2 (2C), 129.3, 129.1 (2C), 128.7 (2C), 128.6 (2C), 127.3 (2C), 126.6 (2C), 
119.3, 84.5, 81.1, 79.1, 76.5, 75.6, 75.2, 74.5, 72.1 (d), 68.1, 68.0, 63.8, 58.5, 52.8, 46.7, 45.6, 
43.2, 37.1, 36.5, 35.6, 31.9, 31.4, 29.6 (2C), 29.5, 29.4, 29.3, 29.1, 28.9, 27.7, 26.8, 25.0, 
24.9, 24.8, 24.2, 22.8, 22.7, 22.2, 20.8, 14.8, 14.1, 9.6. MS (ESI+): m/z = 1363.3 (M + Na)
+
. 
Polymerization of OEGMA from Ptx-digly-CDP. Ptx-digly-CDP (53.6 mg, 0.04 mmol), 
AIBN (0.7 mg, 0.004 mmol), OEGMA (0.24 g, 0.80 mmol) and DMF (1.2 mL) were placed 
into a glass vial and the resulting solution was purged with argon for 30 min. The tube was 
placed in an oil bath at 70 °C for 4 h and then cooled to room temperature by placing in a bath 
of cold water. The residue was concentrated under reduced pressure and precipitated in 
cyclohexane and ether to give Ptx-digly-POEGMA as a yellow viscous liquid (P6). Another 
polymerization was performed for 4 h with [OEGMA]0/[Ptx-digly-CDP]0 = 30/1 (P7). 
 
Nanoparticle preparation  
Nanoparticles were prepared by the nanoprecipitation technique. Briefly, 1.0 mg of the 
corresponding polymer was dissolved in 0.5 mL of THF, and added dropwise to 1 mL MilliQ 
water under stirring. THF was evaporated at ambient temperature using a rotary evaporator. 
Average diameter (Dz) and zeta potential measurements were carried out in triplicate. 
 
Critical aggregation concentration  
Solvent-assisted solubilization method was used to prepare the samples for fluorescence 
experiments (i.e., to uniformly distribute the C153 fluorescent dye in the micelle cores).
45
 
THF was used because it is a good solvent for the polymer and for the dye. For P4 (Ptx-digly-
PI), a set of solution was prepared with polymer concentrations varying from 0.0001 mg.mL
-1 
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to 0.5 mg.mL
-1
 whereas for P6 and P7 (Ptx-digly-POEGMA), a set of solutions were prepared 
with polymer concentrations varying from 0.001 mg.mL
-1
 to 2 mg.mL
-1
. All solutions 
contained the same amount of C153 (3.10
-2
 mM). First, concentrated solutions of polymer and 
C153 were prepared in THF. The appropriate volume of both polymer and C153 solutions 
was transferred into small vials and water was added dropwise under gentle stirring. The final 
solutions (always containing less than 10% v/v of THF) were equilibrated for at least 24 h at 
room temperature. Fluorescence spectra were recorded in 10 mm optical path length quartz 
cell. Maximum fluorescence intensities vs log(concentration) were plotted and CAC were 
graphically determined when the slope change.   
 
Drug release 
To determine the Ptx release kinetics from the polymer prodrug nanoparticles, 100 µL of 
nanoparticles Ptx-digly-PI (4.0 mg.mL
-1
) or Ptx-digly-POEGMA (2.0 mg.mL
-1
) were added to 
900 µL of human serum or PBS solution. The mixture was incubated at 37 °C, and aliquots 
(100 µL) of incubation medium were removed at different time points, spiked with 4 µL of 
500 µM N-octylbenzamide (Internal Standard) before addition of 1 mL of a mixture of 
acetonitrile/methanol (90/10, v/v) and ultracentrifugated (15000 G, 20 min, 4 °C). 
Supernatant was then evaporated to dryness under a nitrogen flow at 30 °C. The released drug 
was quantified by reverse-phase HPLC (Waters, Milford, MA 01757, USA) with a C18 
column. Briefly, the chromatographic system consisted of a Waters 1525 Binary LC pump, a 
Waters 2707 Autosampler, a C18 Uptisphere column (3 µm, 150 × 4.6 mm, Interchim), 
HPLC column temperature controllers (model 7950 column heater and chiller, Jones 
Chromatography, Lakewood, CO), and a Waters 2998 programmable photodiode-array 
detector. The HPLC column was maintained at 30 °C. Detection was monitored at 227 nm. 
The HPLC mobile phase was acetonitrile/water (70/30, v/v). The residues were dissolved in 
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100 µL of mobile phase and elution was carried out at a flow rate of 1.0 mL/min isocratically 
for 7 min with acetonitrile/water (70/30, v/v) followed by a 1 min linear gradient to 95% 
acetonitrile. This was followed by a 15-min hold at 95% acetonitrile, and a 1 min linear 
gradient back to acetonitrile/water (70/30, v/v). The system was held for 6 min for 
equilibration back to initial conditions. 
 
Biological activity experiments 
Cell Lines and Cell Culture. Murine leu emia cell line L1210 was  indly provided by Dr. 
Lars  etter Jordheim ( niversit  Claude Bernard Lyon  , Lyon, France), maintained as 
recommended. Lung carcinoma cell line A549, and breast adenocarcinoma cell line MCF-7 
were obtained from the American Type Culture Collection and maintained as recommended. 
Briefly, all cells were cultured in Dulbecco′s minimal essential medium (DMEM). All media 
were supplemented with 10% heat-inactivated FBS (56 °C, 30 min) and penicillin (100 
U.mL
−1
). Cells were maintained in a humid atmosphere at 37 °C with 5% CO2.  
Cell imaging. A549 cells were cultured in a culture dish for 24 h to achieve confluence. Cells 
were then incubated with Ptx-digly-PI/Napht-PI or Ptx-digly-POEGMA/Napht-PI 
nanoparticles (1 wt.% of dye content), at a concentration of 10 μg.mL-1 at 37 °C for 20 h, then 
incubated with LysoTracker Red for 30 min and Hoechst 33342 for 20 min under same 
conditions. After treatment, the cells were washed with Dulbecco’s phosphate buffered saline 
(PBS) and imaged using a confocal microscope (Zeiss) with a ×60 oil-immersion objective. 
The excitation wavelength was 405 nm and 543 nm, and the fluorescence was collected in the 
range of 410–440 m, 450–560 nm, and 569–682 nm, respectively.  
In vitro anticancer activity. The cytotoxicity of the different polymer prodrug nanoparticles 
and Ptx was investigated by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
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bromide] viability test on L1210, A549 and MCF-7 cell lines. Briefly, cells (5 × 10
3
/well) 
were seeded in 96-well plates for 24 h incubation (only 1 h of incubation for L1210 cells), 
then the cells were exposed to a series of concentrations of different polymer prodrug 
nanoparticles, control polymer nanoparticles, or free Ptx for 72 h. After drug exposition, the 
medium was added with 20 μL of MTT solution (5 mg.mL-1 in PBS) for each well. The plates 
were incubated for 1 h at 37 °C and the medium was removed (by centrifugation for L1210). 
200 μL of DMSO were then added to each well to dissolve the precipitates. Absorbance was 
measured at 570 nm using a plate reader (Metertech Σ 960, Fisher Biobloc ,  ll irch, France). 
The percentage of surviving cells was calculated as the absorbance ratio of treated to 
untreated cells. The inhibitory concentration 50% (IC50) of the treatments was determined 
from the dose-response curve. All experiments were set up in quadruplicate to determine 
means and SDs.  
 
Results and Discussion 
Synthesis of Ptx-based polymer prodrugs 
Derivatization of Ptx was achieved by two different pathways; each of them using one 
particular RDRP technique. Not only it gives more flexibility in terms of macromolecular 
engineering and polymer prodrug synthesis, but it allows to take advantage of the different 
benefits of each polymerization method. Herein, it is applied to the synthesis of a Ptx-bearing 
alkoxyamine and a Ptx-bearing RAFT agent for conducting NMP or RAFT polymerization, 
respectively (Figure 1). These two RDRP methods were selected given their well-known 
advantages in terms of simplicity, innocuousness and robustness. 
Derivatization of Ptx was selectively performed on its C-2’-hydroxyl group to 
preserved its bioacitivity.
46
 Esterification was achieved by EDC/DMAP-assisted coupling 
chemistry with an alkoxyamine initiator based on the nitroxide SG1 (AMA-SG1),
43
 and a 
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chain transfer agent (CTA) based on 4-cyano-4-
[(dodecylsulfanylthiocarbonyl)sulfanyl]pentanol (CDP). AMA-SG1 and CDP were previously 
reacted with diglycolic anhydride, giving digly-AMA-SG1 and digly-CDP (Figure 1), to 
position a diglycolate linker in between the drug and the RDRP moiety to promote drug 
release.
36
 When compared to a single ester bond, the diglycolate group has indeed been shown 
to endow the drug-polymer conjugates with greater drug release kinetics, resulting in an 
enhanced therapeutic effect. The resulting Ptx-digly-AMA-SG1 and Ptx-digly-CDP (Figure 1) 
were obtained with 82% and 43% coupling yields, respectively (see experimental part, 
Figures S1 and S2).  
 
 
Figure 1. Synthesis of hydrophobic paclitaxel-diglycolate-polyisoprene (Ptx-digly-PI) and 
PEGylated paclitaxel-diglycolate-poly[oligo(ethylene glycol) methyl ether methacrylate)300] 
(Ptx-digly-POEGMA300) prodrugs by nitroxide-mediated polymerization (NMP) and 
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reversible addition-fragmentation chain transfer (RAFT) polymerization, respectively. 
To obtain all-hydrophobic polymer prodrugs, the polymerization of isoprene was initiated by 
Ptx-digly-AMA-SG1 to grow short polyisoprene (PI) chains from Ptx and achieve well-
defined Ptx-digly-PI prodrugs. PI was selected given its chemical
23
 and enzymatic
47
 
degradability, as well as its biocompatibility,
48
 and its structural similarity with many 
biocompatible natural terpenoids (e.g., retinol, vitamin E). Also, NMP of isoprene is known to 
give well-controlled PI chains from a variety of different SG1-based functional 
alkoxyamines.
44
 A library of well-defined Ptx-digly-PI conjugates with variable chain length 
were successfully obtained by varying the polymerization time from 4 to 16 h and the 
[isoprene]0/[Ptx-digly-AMA-SG1]0 ratio from 200/1 to 400/1 (see experimental part, Table 1, 
Figures S3 and S4). Mn of the purified Ptx-digly-PI prodrugs (Table 1) ranged from 2640 to 
4310 g.mol
-1
 (P1–P5) and had low dispersities (Ð = 1.07–1.10), as demonstrated by 1H-NMR 
spectroscopy and SEC. By tuning the PI chain length, the drug loading varied from ~32 to 
~20 wt.%, which represents high values compared to traditional Ptx-loaded polymer 
nanoparticles where drug loadings usually reach just a few percent. 
 To obtain PEGylated Ptx-polymer prodrug nanocarriers without requiring post-
stabilization by PEG-based surfactants, Ptx-digly-CDP was used to perform the RAFT 
polymerization of oligo(ethylene glycol) methyl ether methacrylate (Mn = 300 g.mol
-1
, 
OEGMA300). POEGMA derivatives have been extensively used as alternative to linear PEGs 
for protein bioconjugation or for the coating of nanoparticles owing to their favorable 
properties (e.g., water-solubility, biocompatibility, stealthiness, etc.).
49
 However, it has never 
been used to prepare PEGylated drug-initiated polymer prodrugs. The RAFT polymerization 
was conducted at two different [OEGMA]0/[Ptx-digly-CDP]0 ratios (20:1 and 30:1), resulting 
in well-defined Ptx-digly-POEGMA conjugates P6 (Mn,SEC = 5580 g.mol
-1
,  Ð = 1.19) and P7 
(Mn,SEC = 7530 g.mol
-1
, Ð = 1.26), respectively, as shown in Table 1 and in Figures S5–S6. 
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Drug loadings were calculated to be 15.3 for P6 and 11.3 wt.% for P7. 
Table 1. Characterization of Ptx-digly-PI and Ptx-digly-POEGMA Polymer Prodrugs and 
Nanoparticles. 
Sample Polymer Mn,SEC
a 
(g.mol
-1
) 
DPn,SEC
b
 DPn,NMR
c
 Ð
a 
 
Dz
d 
(nm) 
PSD
d 
e 
(mV) 
%Ptx
f
 
(wt.%) 
P1 PI 2640 18 24 1.07 236 0.10 -77 32.3 
P2 PI 2670 19 24 1.08 217 0.09 -76 32.0 
P3 PI 2790 21 33 1.08 145 0.07 -61 30.6 
P4 PI 3560 32 42 1.08 133 0.18 -63 24.0 
P5 PI 4310 43 51 1.10 111 0.07 -63 19.8 
P6 POEGMA 5580 14 7 1.19 133 0.06 -35 15.3 
P7 POEGMA 7530 21 9 1.26 151 0.15 -33 11.3 
a
Determined by SEC, calibrated with PS standards and converted into PI by using Mark-Houwink-Sakurada 
parameters for Ptx-digly-PI
44
 and calibrated with PMMA standards for Ptx-digly-POEGMA.
b
 Calculated 
according to DPn,SEC = (Mn,SEC – MWalkoxyamine)/MWisoprene for Ptx-digly-PI and (Mn,SEC – MWCTA)/MWOEGMA for 
Ptx-digly-POEGMA. 
c
Calculated from ratio of areas under the peak at 7.1-8.2 ppm (proton on the benzene of 
Ptx) and 5.0–5.5 ppm (vinylic H in isoprene repeat unit (1,4-addition), corresponding to ~81% of total isoprene 
units) for Ptx-digly-PI,
44
 and calculated from the ratio of areas under the peak at 7.1-8.2 ppm (proton on the 
benzene of Ptx) and 3.3-4.3 ppm (OEG protons) for Ptx-digly-POEGMA. 
d
Determined by DLS. 
e
Zeta potential. 
f
%Ptx = MWPtx/Mn,polymer.  
 
Formulation into nanoparticles and physicochemical properties 
The critical aggregation concentrations (CAC) of Ptx-digly-PI and Ptx-digly-POEGMA 
prodrugs in water were first determined to evaluate their ability to self-assemble into 
nanoparticles. Measurements were performed by means of fluorescence spectroscopy by 
using coumarin 153 (C153), which is an appropriate dye to study self-assembly in water.
45
 
Ptx-digly-PI led to CAC = 3.9 g.mL-1 for P4 (Figure 2a) whereas PEGylated Ptx-digly-
POEGMA led to CAC = 77.6 and 21.4 g.mL
-1
 for P6 and P7, respectively (Figure 2b). As 
expected because of their hydrophobic nature, Ptx-digly-PI prodrugs exhibited a much lower 
CAC than those of Ptx-digly-POEGMA. These values are nevertheless small enough to allow 
formation of nanoparticles at concentrations usually employed from drug delivery purposes 
(ca. mg.mL
-1
). 
18 
 
 
Figure 2. Measurement of the critical aggregation concentration of (a) Ptx-digly-PI P4 and 
(b) Ptx-digly-POEGMA P6 and P7 in water determined by fluorescence spectroscopy using 
coumarin 153. Representative cryogenic transmission electron microscopy (cryo-TEM) 
images of nanoparticles (c) P4 and (d) P6 at 5 mg.mL
-1
. 
 
The different prodrugs were then formulated into nanoparticles by the nanoprecipitation 
method to target a final concentration of 1 mg.mL
-1
. As shown in Table 1, Ptx-digly-PI 
nanoparticles were formed with average diameters in the 111–236 nm range and narrow 
particle size distributions (PSD ~0.1). Interestingly, the average diameter of Ptx-digly-PI 
nanoparticles gradually decreased from 236 to 111 nm with an increase of the PI chain length. 
This trend may be assigned to a higher compaction of the longer polymer chains due to 
increased hydrophobic interactions/lower solubility. Ptx-digly-POEGMA nanoparticles also 
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displayed average diameters (133–151 nm) in the suitable window for drug delivery purposes 
together with narrow particle size distributions (Table 1). Representative cryogenic 
transmission electron microscopy (Cryo-TEM) images of both types of nanoparticles showed 
spherical morphologies and colloidal characteristics that were in good agreement with DLS 
data (Figure 2c, 2d and Table S1). For instance, for nanoparticles P4, the number-average 
diameter (Dn) determined from cryo-TEM images was equal to 141 nm whereas from DLS, a 
z-average diameter (Dz) of 133 nm was obtained. Interestingly, for nanoparticles P6, Dn was 
significantly smaller than Dz (92 vs. 133 nm, respectively), which is likely related to the 
overestimated hydrodynamic volume determined by DLS because of surface POEGMA 
chains. To the best of our knowledge, efficient colloidal stability of all-hydrophobic Ptx-
initiated polymer prodrug nanoparticles is still an unmet challenge. Indeed, it was shown that 
Ptx-PLA nanoparticles (the only example of such a system reported so far) led to immediate 
aggregation (i.e., within minutes) after addition of PBS,
32
 presumably because of salt-induced 
screening of the repulsive forces.
50
 Herein, the Ptx-digly-PI nanoparticles exhibited excellent 
colloidal stability in water (Figure 3a and 3b), cell culture medium (Figure 3a and 3b) and 
PBS (Figure S7), with very little variation of the average diameter and the particle size 
distribution from a few weeks to nearly 3 months. Such high colloidal stability is key as the 
integrity of the nanoparticles will be maintained in biological fluids post-administration. This 
unique feature is likely the result of the strong hydrophobic interactions between PI chains 
together with the efficient electrostatic stabilization provided by the strongly negative surface 
charges, ranging from −61 to −77 mV, as shown by zeta potential measurements (Table 1). 
The colloidal stability of Ptx-digly-POEGMA nanoparticles was also assessed in water as 
shown in Figure S8. 
 
 
20 
 
 
Figure 3. Evolution with time of (a) the average diameter and (b) the particle size distribution 
of Ptx-digly-PI nanoparticles P1–P5 in water (plain symbols) and in cell culture medium 
(open symbols) determined by DLS.  
 
In addition, the average diameter of Ptx-digly-PI nanoparticles can also be tuned by varying 
the nanoparticle concentration during nanoprecipitation process: the higher the concentration, 
the higher the average diameter. For instance, when the polymer concentration was varied 
from 0.5 to 2.5 mg.mL
-1
 at a fixed THF/water volume ratio, a gradual increase of the average 
diameter from 104 nm to 177 nm was observed (Figure S9).  
 
Drug release in different media 
The release of Ptx from Ptx-digly-PI and Ptx-digly-POEGMA nanoparticles was monitored 
by HPLC in different media (PBS and human serum) to probe the influence of the nature of 
the polymer and of the incubation medium over the Ptx release kinetics (Figure 4). Whereas 
incubation of Ptx-digly-PI nanoparticles in PBS gave nearly no Ptx release (< 0.3% after 24 h) 
whatever the Mn tested, a moderate release of Ptx (~3–5 % after 24 h) was however observed 
in human serum under identical experimental conditions (Figure 4a). Although these results 
confirmed the susceptibility of the diglycolate linker to be more prone to cleavage in a 
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biological medium, the amount of released Ptx is significantly lower than analogous prodrugs 
bearing hydrophilic drugs such as cladribine.
36,38
 The strongly hydrophobic environment 
induced by both Ptx and PI nearby the drug-polymer linkage is likely to strongly prevent its 
rapid cleavage, thus resulting in slow Ptx release.  
 
Figure 4. Ptx release profiles at 37 °C from (a) Ptx-digly-PI (P3–P5) nanoparticles and (b) 
Ptx-digly-POEGMA nanoparticles (P6, P7) in human serum (plain symbols) and in PBS 
(open symbols) determined by HPLC. 
 
Conversely, Ptx-digly-POEGMA nanoparticles P6 and P7 exhibited significant Ptx release in 
human serum, reaching ~30% of the total Ptx content after 24 h incubation (note that ~25% 
Ptx release was already observed in less than 10 h). The water-solubility of POEGMA likely 
counterbalanced the strong hydrophobicity of Ptx, which promoted enzymatic cleavage of the 
diglycolate linker. Interestingly, incubation of nanoparticles P6 and P7 in PBS led to 5% and 
14% drug release, respectively. Conversely to Ptx-digly-PI nanoparticles, these results tend to 
show that hydrolytic cleavage of the diglycolate linker from Ptx-digly-POEGMA 
nanoparticles does occur in PBS, providing a sufficient hydrophilic environment in the 
vicinity of the drug-polymer linkage.  
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Evaluation of the biological performances  
To show the versatility and the robustness of the two different systems, the in vitro 
cytotoxicity of Ptx-digly-PI and Ptx-digly-POEGMA nanoparticles was then investigated by 
cell viability assay (MTT) on three different cancer cell lines: murine leukemia (L1210), 
human lung carcinoma (A549) and breast adenocarcinoma (MCF-7). Ptx-digly-PI 
nanoparticles (P1–P5) led to significant cytotoxicity to L1210 cells whereas control AMA-
digly-PI nanoparticles were not cytotoxic (Figure 5a). Interestingly, the IC50 of P1–P5 
nanoparticles gradually decreased from 635 to 90 nM (Figure 5b) with the increase of the PI 
chain length (Mn = 2610–4310 g.mol
-1
), and approached the IC50 of free Ptx (IC50 = 20 nM). 
This Mn vs. IC50 trend is likely assigned to two parameters which may strongly influence the 
cellular uptake of the nanoparticles by cancer cells and eventually the cytotoxicity: (i) the 
nanoparticle size, that is smaller for higher Mn and/or (ii) a change in the composition of the 
nanoparticle corona, that is known to play a pivotal role in the nanoparticle fate
51
 (herein, a 
more hydrophobic surface is expected for a higher Mn). On A549 cells, Ptx-digly-PI (P3–P5) 
nanoparticles gave very similar cytotoxicity profiles, with even greater cytotoxicity, whereas 
Ptx-free AMA-digly-PI nanoparticles were still not cytotoxic (Figure 5c). Here again, 
gradually increasing the Mn of Ptx-digly-PI from 2790 to 4310 g.mol
-1
 enabled a decrease in 
the IC50 of the corresponding nanoparticles from 132 to 8 nM (Figure 5d), thus reaching the 
same IC50 as free Ptx (6 nM).  
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Figure 5. Cytotoxicity assay on (a) L1210 cells and (c) A549 cells with increasing 
concentrations of Ptx-digly-PI nanoparticles P1–P5, AMA-digly-PI and free Ptx after an 
incubation period of 72 h. The horizontal dashed line indicates the IC50. Evolution of the IC50 
of Ptx-digly-PI nanoparticles P1–P5 as function of the Mn after cytotoxicity assay on (b) 
L1210 cells and (d) A549 cells. The horizontal dashed line indicates the IC50. 
 
Switching from fully hydrophobic Ptx-digly-PI nanoparticles to PEGylated Ptx-digly-
POEGMA nanoparticles also resulted in strong cytotoxicity on both L1210 and A549 cell 
lines (Figur 6). Importantly, the IC50 values were very close, if not lower, than that of free Ptx, 
thus indicating high anticancer activity. On L1210 cells, the IC50 of Ptx-digly-POEGMA P6–
P7 nanoparticles was equal to 30 nM (IC50 Ptx = 20 nM), whereas on A549 cells it was in the 
4–9 nM range (IC50 Ptx = 6 nM). These remarkable results can be correlated with the greater 
Ptx release profiles in human serum of Ptx-digly-POEGMA nanoparticles compared to those 
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of Ptx-digly-PI nanoparticles (Figure 4). Conversely to Ptx-digly-PI nanoparticles, no 
apparent chain-length dependency was however observed with Ptx-digly-POEGMA 
nanoparticles. This observation may be correlated to a marginal difference in terms of average 
diameter for the two Ptx-digly-POEGMA conjugates used (Table 1). 
 
 
Figure 6. Cytotoxicity assay on (a) L1210 cells or (b) A549 cells with increasing 
concentrations of Ptx-digly-POEGMA nanoparticles P6–P7, AMA-digly-POEGMA and free 
Ptx after an incubation period of 72 h. The horizontal dashed line indicates the IC50.  
 
The most cytotoxic Ptx-based polymer prodrug nanoparticles from each series (i.e., Ptx-digly-
PI P5 and Ptx-digly-POEGMA P6) were then tested for their cytotoxicity on MCF-7 as a third 
cancer cell line to demonstrate the broad efficacy of our materials. They both led to high 
cytotoxicity with IC50 value of 27 nM and 8 nM, respectively (Figure S10), whereas the IC50 
of free Ptx on this cell line was equal to 25 nM.
52
 
 
Internalization into cancer cells 
To give insight on the uptake mechanism, the in vitro fate of Ptx-digly-PI P5 and Ptx-digly-
POEGMA P6 nanoparticles was then investigated in A549 cells by means of confocal 
microscopy. To accurately study the subcellular localization of the nanoparticles, they were 
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prepared by co-nanoprecipitation of the desired prodrug with a small amount of a similarly-
constructed fluorescent naphthalimide-polyisoprene (Napht-PI, Mn = 3700 g.mol
-1
, Đ = 1.20, 
1 wt.% dye content) exhibiting aggregation-induced emission (AIE) properties.
37,53
 
Conversely to the traditional encapsulation of a free hydrophobic dye, this approach rules out 
potential leakage of the dye from the nanoparticles (leading to confocal image 
misinterpretation),
54
 enables sharp fluorescence signal and accurate subcellular localization.  
 A549 cells were incubated for 24 h with the fluorescently-labeled prodrug 
nanoparticles P5 and P6, after staining of lysosomes and nuclei by LysoTracker Red and 
Hoechst 33342, respectively. As shown in Figures 7 and 8, a bright green fluorescence signal 
from P5 or P6 (green channel, 450–560 nm, λex = 405 nm) was observed in A549 cells 
demonstrating their efficient internalization. By overlaying this channel with the red 
(569−682 nm, λex = 543 nm) and blue (410−440 nm, λex = 405 nm) channels, an intense 
yellow/orange colocalization signal was observed in both cases. These results demonstrated 
that Ptx-digly-PI and Ptx-digly-POEGMA nanoparticles were located in the lysosomes and 
strongly supported an internalization mechanism by endocytosis.  
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Figure 7. (a) Nomarski image of A549 cells; (b–d) confocal microscopy images [(b) blue 
(Hoechst 33342), (c) red (LysoTracker Red) and (d) green (Napht)]; (e) merge of confocal 
microscopy images (b–d) and (f) merge of Nomarski image with confocal microscopy images 
(b–d), after a 24 h incubation of A549 cells with Ptx-digly-PI P5 nanoparticles. Scale bar = 20 
m. 
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Figure 8. (a) Nomarski image of A549 cells; (b–d) confocal microscopy images [(b) blue 
(Hoechst 33342), (c) red (LysoTracker Red) and (d) green (Napht)]; (e) merge of confocal 
microscopy images (b–d) and (f) merge of Nomarski image with confocal microscopy images 
(b–d), after a 24 h incubation of A549 cells with Ptx-digly-POEGMA P6 nanoparticles. Scale 
bar = 50 m. 
 
 
Conclusion 
The versatile derivatization of Ptx was achieved by means of the drug-initiated method and 
illustrated by the synthesis of various well-defined Ptx-based polymer prodrugs with high 
drug loadings from two different RDRP techniques. It enabled, for the first time, the 
formation of either self-stabilized, all-hydrophobic Ptx-polymer prodrug nanoparticles or their 
PEGylated counterparts, thus conferring great flexibility in regard the development of 
nanocarriers for drug delivery. Remarkably, their biological evaluations gave high 
cytotoxicity on three different cancer cell lines, with chain length-cytotoxicity dependency 
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and IC50 values comparable to those of the parent drug. This work not only further 
demonstrates the robustness and the broad use of the drug-initiated method for the simple 
design of efficient polymer prodrug nanoparticles, but it also opens new perspectives in the 
field of nanomedicine as it shows that polymers of opposite nature (i.e., hydrophobic and 
water-soluble) can successfully be grown from Ptx, leading in both cases to efficient 
anticancer nanoparticles with very different surfaces properties.  
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